COMMUNIQUÉS West-GlobeNewswire

Cartesian Therapeutics Announces New Employment Inducement Grants

07/08/2024 - 22:05

GAITHERSBURG, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune [...]

ICU Medical Announces Second Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance

07/08/2024 - 22:05

SAN CLEMENTE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the [...]

Silk Road Medical Reports Second Quarter 2024 Financial Results

07/08/2024 - 22:05

SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three [...]

ClearPoint Neuro Reports Second Quarter 2024 Results

07/08/2024 - 22:05

Second Quarter Revenue Growth +32%; Record Revenue Achieved SOLANA BEACH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company [...]

Maravai LifeSciences Reports Second Quarter 2024 Financial Results

07/08/2024 - 22:05

Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of [...]

Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

07/08/2024 - 22:05

Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q’24 Bemnifosbuvir and Ruzasvir HCV Data Presented at EASL: Support Best-in-Class Potential with High Antiviral [...]

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

07/08/2024 - 22:05

Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients treated with bexotegrast Positive long-term data from INTEGRIS- [...]

PacBio Announces Second Quarter 2024 Financial Results

07/08/2024 - 22:05

MENLO PARK, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2024. Second quarter results: Revenue of $36.0 million compared with $47.6 [...]

Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast

07/08/2024 - 22:05

TARRYTOWN, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) announces the following September 2024 investor events: Investor Conference Presentations • Morgan Stanley 22 nd Annual [...]

Elutia Announces Second Quarter 2024 Results

07/08/2024 - 22:05

Launch Production of EluPro® Underway, Commercial Team Expansion Continues, Financial Position Solidified SILVER SPRING, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a [...]

Generation Bio Reports Second Quarter 2024 Financial Results

07/08/2024 - 22:05

Cash balance of $217 million still expected to fund operations into 2H 2027 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology company innovating genetic medicines [...]

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

07/08/2024 - 22:05

Outcome of pre-planned Reliance II interim analysis anticipated by YE 2024 Enrollment in Phase 3 Reliance II study expected to be completed by YE 2024 Preparations on track to initiate Phase 1 study for REL-P11 for [...]

Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

07/08/2024 - 22:05

-Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment of Duchenne Muscular Dystrophy- -Phase 3, HOPE-3 Trial of Deramiocel in DMD Fully Enrolled; On [...]

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

07/08/2024 - 22:05

REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

07/08/2024 - 22:02

Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024 Patient Screening for Minimal Residual Disease (MRD) and Enrollment Proceeding [...]

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

07/08/2024 - 22:02

SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, [...]

Keros Therapeutics Reports Second Quarter 2024 Financial Results

07/08/2024 - 22:01

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]

electroCore Announces Second Quarter 2024 Financial Results

07/08/2024 - 22:01

Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023 Company to host a conference call and webcast today, August 7, 2024 at 4:30 PM EST ROCKAWAY, N.J., Aug. 07, [...]

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

07/08/2024 - 22:01

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye to [...]